Rituximab Plus Lenalidomide Improves the Complete Remission Rate in Comparison with Rituximab Monotherapy in Untreated Follicular Lymphoma Patients in Need of Therapy. Primary Endpoint Analysis of the Randomized Phase-2 Trial SAKK 35/10
Eva Kimby(Karolinska University Hospital), Emanuele Zucca(Università della Svizzera italiana), Thilo Zander(Luzerner Kantonsspital), Hanne Bersvendsen(University Hospital of North Norway), Peter de Nully Brown(Copenhagen University Hospital), Hans Hagberg(Uppsala University Hospital), Fatime Krasniqi(University Hospital of Basel), Hanne Hawle(Swiss Group For Clinical Cancer Research), Ulrich Mey(Kantonsspital Graubünden), Simona Berardi(Swiss Group For Clinical Cancer Research), Walter Mingrone(Kantonsschule Olten), Micaela Hernberg(Apple (Israel)), Björn E. Wahlin(Karolinska University Hospital), Urban Novak(University of Bern), Mario Bargetzi(Kantonsspital Aarau), Giovanni Martinelli(University of Bologna), Bjørn Østenstad(Oslo University Hospital), Andreas Lohri(Kantonsspital St. Gallen), Andrés J.M. Ferreri(Vita-Salute San Raffaele University), Steffi Demmel(Swiss Group For Clinical Cancer Research), Stéphanie Rondeau(Kantonsspital St. Gallen), Ann‐Sofie Johansson(University Hospital of Umeå), Daniel Rauch(Washington University in St. Louis), Stephan Dirnhofer(University of Basel), Felicitas Hitz(Kantonsspital St. Gallen)
Cited by 18
Related Papers
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
|Blood|2022|1.5k
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
|New England Journal of Medicine|2019|1.3k